Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
March 07, 2024 07:26 ET
|
Arch Biopartners
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in...
Ant Financial Ranked #6 in Fortune’s List of Companies that Change the World
September 08, 2017 05:04 ET
|
Ant Financial Services Group
Ant recognized for environmental impact of Ant Forest initiativeAnt the highest ranked Asia-headquartered company HANGZHOU, China, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Ant Financial has been named #6...